Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS
Reuters
Jun 05
Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS
Immunic, Inc., a biotechnology company specializing in treatments for chronic inflammatory and autoimmune diseases, has completed enrollment for its phase 3 ENSURE trials for vidofludimus calcium in patients with relapsing multiple sclerosis $(RMS.AU)$. Involving over 2,200 participants, these trials represent a significant milestone toward potential regulatory approval and commercialization. The company expects top-line data by the end of 2026. Additionally, new data from the phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) highlights the neuroprotective potential of vidofludimus calcium, showing substantial reductions in time to 24-week confirmed disability worsening compared to a placebo. Dr. Daniel Vitt, CEO of Immunic, emphasized the drug's promising safety profile and its potential to transform the oral MS therapy market by offering a novel treatment option with neuroprotective, anti-inflammatory, and antiviral effects.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03900) on June 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.